March/April 2012, Vol 5, No 2

Page 1

THE PEER-REVIEWED FORUM FOR EVIDENCE IN BENEFIT DESIGN ™ MARCH/APRIL 2012

VOLUME 5, NUMBER 2

FOR PAYERS, PURCHASERS, POLICYMAKERS, AND OTHER HEALTHCARE STAKEHOLDERS

EDITORIAL

A New Beginning David B. Nash, MD, MBA BUSINESS

Trends in Biologic Therapies for Rheumatoid Arthritis: Results from a Survey of Payers and Providers ™

Rhonda Greenapple, MSPH Stakeholder Perspective by Albert Tzeel, MD, MHSA, FACPE

Impact of the Removal of the Monthly Liver Function Test Requirement for Ambrisentan Louise A. Durst, RN; John Carlsen, MHA; Megan Kuchinski, MPH; Lauren Harner, JD; Daniel Neves, BA; Stephanie J. Harris, RN, BSN; Glenna L. Traiger, RN, MSN, CNS-BC Stakeholder Perspective by James T. Kenney, Jr, RPh, MBA CLINICAL

Benefits of Novel Oral Anticoagulant Agents for Thromboprophylaxis after Total Hip or Knee Arthroplasty Richard J. Friedman, MD, FRCSC Stakeholder Perspective by Atheer A. Kaddis, PharmD

©2012 Engage Healthcare Communications, LLC www.AHDBonline.com


Turn static files into dynamic content formats.

Create a flipbook
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.